INBX
Inhibrx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Beats Expectation
Consecutive Revenue Decline
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INBX
Inhibrx Biosciences, Inc.
A biotechnology company committed to researching and developing new biological agents for the treatment of various diseases.
11025 N. Torrey Pines Road, Suite 140 La Jolla, California 92037
--
Inhibrx Biosciences, Inc., was incorporated under the laws of the State of Delaware on January 8, 2024 and is a direct, wholly owned subsidiary of Inhibrx, Inc. The Company is a clinical-stage biopharmaceutical company with a portfolio of novel biotherapeutic drug candidates developed using its proprietary modular protein engineering platform.
Company Financials
EPS
INBX has released its 2025 Q3 earnings. EPS was reported at -2.28, versus the expected -1.72, missing expectations. The chart below visualizes how INBX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
